Tumor lymphangiogenesis and melanoma metastasis

Malignant melanomas of the skin primarily metastasize to lymph nodes, and the detection of sentinel lymph node metastases serves as an important prognostic parameter. There is now compelling evidence that melanomas can induce lymphangiogenesis (growth of lymphatic vessels), mainly at the tumor–strom...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular physiology Vol. 216; no. 2; pp. 347 - 354
Main Authors: Rinderknecht, Matthias, Detmar, Michael
Format: Journal Article
Language:English
Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.08.2008
Subjects:
ISSN:0021-9541, 1097-4652, 1097-4652
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Malignant melanomas of the skin primarily metastasize to lymph nodes, and the detection of sentinel lymph node metastases serves as an important prognostic parameter. There is now compelling evidence that melanomas can induce lymphangiogenesis (growth of lymphatic vessels), mainly at the tumor–stroma interface, and that the level of tumor lymphangiogenesis is correlated with the incidence of sentinel lymph node metastases and with disease‐free survival. Thus, tumor lymphangiogenesis can serve as a novel prognostic predictor in melanoma. Vascular endothelial growth factor (VEGF)‐C, released by melanoma cells and by tumor‐associated macrophages, likely represents the major lymphangiogenic factor in melanoma, although other members of the VEGF family might also be involved. The recent discovery that tumors can induce a premetastatic niche, by inducing lymphatic vessel growth in sentinel lymph nodes even before metastasis, and that lymph node lymphangiogenesis enhances metastatic spread, indicates that activated lymphatic vessels represent novel targets for the detection and/or therapy of melanoma metastases. J. Cell. Physiol. 216: 347–354, 2008. © 2008 Wiley‐Liss, Inc.
Bibliography:Commission of the European Communities - No. LSHC-CT-2005-518178
ArticleID:JCP21494
Austrian Science Foundation - No. S9408-B11
National Institutes of Health - No. CA69184
ark:/67375/WNG-9Q9J8G7V-M
Cancer League Zurich
istex:CCBD607FF98EB66F8D3F879DA817C1820A93508E
Swiss National Fund - No. 3100A0-108207
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0021-9541
1097-4652
1097-4652
DOI:10.1002/jcp.21494